

Re-purposing of off-patent drugs for children -TEDDY to create a bridge between Europe and Asia

Prof Ian Wong

UCL School of Pharmacy and
University Hong Kong

European Network of Excellence for Paediatric Clinical Research

Background

- New drug development is expensive and high risk.
- Lack of research and development of appropriate formulation medications for
 - Children
 - Old people



Interests from Asian Countries

- Asian countries (except Japan) is less well developed in biopharmaceutical industry
 - Mainly generic company to produce local pharmaceutical products
 - Import other medicines from large international companies
- Logical next step is to develop niche products of off-patented medications
 - Repurposing



Background

- Repositional old drugs for new indication is low risk and profitable
- Eg Buccolam developed by Therakind
 - Worldwide sale over US\$ 45million [1]

[1] http://www.evaluategroup.com/View/50554-1002-modData/product/buccolam

BUICCOL AM



Basic concept

Governments Funding

Off patent drugs

Drugs soon off patent

Local
Pharmaceutical
Companies

New products

TEDDY Network Local universities



Private and public partnership

- Government grants are usually available
 - Sometimes up to 50% of the R&D cost
 - Usually need a university partner, they conduct the R&D
 - Usually need a commercial company provide the business plan and commercialization input + matching of the fund.
 - TEDDY has a lot of expertise to offer Asian partners

European Network of Excellence for Paediatric Clinical Research

Current Interests

- Thailand Chulalongkorn University
- Hong Kong University of Hong Kong
- These universities are in the positions to work with TEDDY to develop repurposed medicines for children.
- Discussion is still on-going
- TEDDY can propose new topics and take
 forward with the local partner universities



Questions and discussion

